FETZIMA

Peak

levomilnacipran hydrochloride

NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
0/100

Mechanism of Action

unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of reuptake at serotonin and norepinephrine transporters. Non-clinical studies have shown that levomilnacipran is a potent and selective serotonin and…

Loss of Exclusivity

LOE Date
May 23, 2032
75 months away
Patent Expiry
May 23, 2032
Exclusivity Expiry
Mar 24, 2026

Patent Records (3)

Patent #ExpiryTypeUse Code
RE43879
Jan 11, 2026Expired
U-839
8481598
Mar 2, 2031
U-839
8865937
May 23, 2032
SubstanceProduct